has been documented in multiple studies in dogs, with a prevalence of 32% in dogs with MMVD treated for CHF. [9] [10] [11] [12] [13] [14] These findings, with evidence that mineralocorticoid receptor antagonists showed prognostic benefit in CHF treatment, further suggest the need for improved mitigation of ABT. 15 Angiotensin II receptor blockers (ARB) are used to inhibit the effects of tissue ATII production from non-ACE-dependent pathways.
Despite the beneficial effects of ARB on the inhibition of tissue RAAS, ABT still occurs. [16] [17] [18] The natriuretic peptide (NP) system is activated with cardiovascular disease and antagonizes the RAAS. [19] [20] [21] Neprilysin (NEP) is an enzyme that naturally cleaves NPs, and increased NEP concentrations are positively associated with cardiovascular death and hospitalization in humans with heart failure. 22, 23 A combinational first-in-class angiotensin receptor blocker/NEP inhibitor was developed (sacubitril/valsartan [S/V], Entresto; Novartis Pharmaceuticals, Basel, Switzerland) to decrease the cardiovascular stimulus for RAAS activation, inhibit RAAS hormones, decrease breakdown of endogenous NPs, and decrease the occurrence of ABT. 19 Sacubitril/valsartan showed an overwhelming benefit compared with enalapril in humans with symptomatic heart failure, and it lowered plasma aldosterone concentrations in healthy dogs with diet-induced RAAS activation better than benazepril and valsartan. 24, 25 The aim of our pilot study was to determine the effects of S/V on the RAAS and NP system in dogs with ACVIM Stage B2 MMVD by evaluating urinary aldosterone-to-creatinine ratio (UAldo : C) and plasma NT-proBNP concentrations, respectively, compared with placebo. A second aim of the study was to determine the safety of S/V in dogs with preclinical MMVD by evaluating systolic arterial pressure (SAP) and serum blood urea nitrogen (BUN), creatinine, and electrolyte concentrations. We hypothesized that S/V would have an inhibitory effect on the RAAS compared with placebo in dogs with preclinical MMVD by demonstrating more reduction in the UAldo : C over time, as well as lower plasma NT-proBNP concentrations because of a decrease in cardiovascular stimulation of NP release, without causing adverse effects.
| MATERIALS AND METHODS

| Animals and study timeline
Our study was a prospective, randomized, double-blind, placebocontrolled study. The study was conducted in accordance with the guidelines of the Animal Care and Use Committee of Auburn University (2016-2986) and with informed consent of the owners.
[Correction added after first online publication 31 were determined by discarding the first reading and averaging 5 consecutive SAP readings.
| Diagnostic imaging
Right lateral projections were used to calculate the VHS as previously described. 28 The pulmonary parenchyma was evaluated for evidence of pulmonary edema based on the presence of an interstitial or alveolar pattern and contemporaneous clinical signs.
Echocardiography was performed in all dogs without sedation using an ultrasound unit (Vivid E9, General Electric, Boston, Massachusetts) with a 6 MHz phased array transducer. All echocardio- 
| Statistical analysis
Assessment of data distribution in regard to normality was determined Tables 1 and 2 , respectively.
There were no significant differences in any of these parameters between groups on either day. Each patient's BUN, creatinine, and electrolyte concentrations were within the reference ranges for both groups at day 0, on the 7-day recheck, and at day 30. Abbreviations: Ao, aorta; BUN, blood urea nitrogen; E/E 0 , peak velocity of early diastolic transmitral flow to parietal mitral annular tissue Doppler interrogation E 0 velocity ratio; iLVIDd, left ventricular internal diameter at end-diastole indexed to body weight; K, potassium; LA, left atrium;
LVIDs, left ventricular internal diameter at end-systole indexed to body weight; MV E Vel, peak velocity of early diastolic transmitral flow; Na, sodium; S/V, sacubitril/valsartan; VHS, vertebral heart score. The plasma NT-proBNP concentrations and UAldo : C for each group at day 0 and day 30 are shown in Table 3 . The mean UAldo : C (pmol/mmol) was not significantly different between day 0 and day 30 in both groups (Table 3) Abbreviations: Ao, aorta; BUN, blood urea nitrogen; E/E 0 , peak velocity of early diastolic transmitral flow to parietal mitral annular tissue Doppler interrogation E 0 velocity ratio; iLVIDd, left ventricular internal diameter at end-diastole indexed to body weight; K, potassium; LA, left atrium;
LVIDs, left ventricular internal diameter at end-systole indexed to body weight; MV E Vel, peak velocity of early diastolic transmitral flow; Na, sodium; S/V, sacubitril/valsartan; VHS, vertebral heart score. Continuous variables are reported as mean and SD. Categorical variables are reported as number (%). Abbreviations: NT-proBNP, N-terminal pro-brain natriuretic peptide; S/V, sacubitril/valsartan; UAldo: C, urinary aldosterone to creatinine ratio. Continuous variables are reported as mean and SD.
enzymatic degradation of circulating NPs, sustaining their plasma concentrations. Natriuretic peptides prevent hormonal cascade through the RAAS by inhibiting renin secretion and blocking renal aldosterone receptors. 19 Natriuretic peptide receptors are also present in the zona glomerulosa of the adrenal glands, suggesting the ability of NPs to directly inhibit aldosterone production and release from the adrenal glands. 40 We evaluated the effects of S/V on the NP system by measur- can be explained by the reasons described above, but these would not explain the decrease seen in the placebo group. Limited published information is available on the effect of pimobendan on plasma NT-proBNP concentrations, but a study in dogs with MMVD and PH showed a significant decrease in plasma NTproBNP concentrations after short-term pimobendan administration. 46 Therefore, pimobendan potentially could have caused the decrease in plasma NT-proBNP concentration in both groups. Nterminal pro-brain NP concentrations were used as a marker of NP system activity in this study, but measuring additional markers of the NP system, such as atrial NP, N-terminal pro-atrial NP, and BNP, may be indicated in future studies to obtain a more complete evaluation of the NP system. Sacubitril/valsartan administration over 30 days did not cause any adverse effects on SAP or BUN, creatinine, or electrolyte concentrations in the dogs of this study. Although S/V can cause these derangements in humans, it does so to a lesser extent than does enalapril. 24 On the other hand, clinically irrelevant systemic hypotension was seen more frequently in human patients taking S/V than in those taking enalapril, but S/V did not significantly alter SAP over time in the dogs of our study. 24 Sacubitril/valsartan and related drugs have been shown to be a safe and effective treatment for systemic hypertension in humans and have been shown to delay the progression of chronic and proteinuric kidney diseases. [46] [47] [48] [49] [50] Increased NEP concentrations are present in human patients with end-stage renal dysfunction, suggesting an additional indication for use of S/V in patients with renal disease. 51 Because of these beneficial effects that the NPs have on the cardiovascular and renal systems, drugs such as S/V may have important implications for cardiovascular-renal disorders in dogs. 19, 52 The addition of exogenous NPs to furosemide administration causes more profound diuresis and natriuresis and has the potential to allow for decreases in diuretic dosages, while preventing furosemide-induced RAAS activation. 40, 46, 53, 54 Future studies evaluating the concurrent use of S/V and furosemide are indicated in dogs.
Our study had several limitations. The first is small sample size but ours was a pilot study to determine the safety and effectiveness of S/V in dogs with ACVIM Stage B2 MMVD. Another limitation is the potential effects of chronobiology and diet on the RAAS and NP FIGURE 1 Urinary aldosterone to creatinine ratio percent change from day 0 to day 30 in both groups. Asterisk (*) denotes statistical significance in S/V group compared with placebo, P = .032. UAldo : C: urinary aldosterone to creatinine ratio, S/V: sacubitril/valsartan FIGURE 2 N-terminal pro-brain natriuretic peptide percent change from day 0 to day 30 in both groups. Means were not statistically different between groups, P = .68. NT-proBNP: N-terminal pro-brain natriuretic peptide, S/V: sacubitril/valsartan system. Circadian fluctuations of RAAS hormones and dietary sodium content could have affected our results, but intrapatient variables (feeding times, food types, sample collection times) were held constant for the duration of the study period. 55, 56 Pooled urine samples also were used to minimize the potential effect of these variables on urinary aldosterone concentrations. First-morning urine samples were used, but those samples may not have been representative of overnight urine pooling (ie, the patient may have urinated overnight), which could affect the UAldo : C. We evaluated UAldo : C as a marker of RAAS activation, but there is evidence that early cardiac disease does not lead to increased circulating RAAS hormones in dogs, and RAAS activation may be dependent on duration and severity of cardiac disease. [57] [58] [59] This may not have a relevant impact on the results of our study because each patient was used as its own control over the 30 day-trial and all study dogs had moderate to severe cardiomegaly. Sacubitril/valsartan may have a stronger impact on biomarker concentrations in patients with more profound RAAS activation. Pimobendan was not expected to have an effect on RAAS hormone concentrations, 60 but dogs in our study were receiving other noncardiac medications the effects of which on RAAS hormones are unknown. Lastly, the dosage of S/V used in our study was extrapolated from a previous study using S/V in healthy dogs. 25 Although biological effects were seen at the current dosage used, a higher or lower dosage may produce different results.
| CONCLUSION
Sacubitril/valsartan is effective at lowering urine aldosterone concentrations in asymptomatic dogs with cardiomegaly secondary to MMVD. Using S/V is safe in these patients, with no deleterious effects on BUN, creatinine, and electrolyte concentrations, or SAP.
Additional studies are warranted to evaluate long-term (>30 days) administration of S/V, compare the effects of S/V to ACEI, and evaluate the use of S/V in dogs treated for CHF.
